<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831518</url>
  </required_header>
  <id_info>
    <org_study_id>STHCIT1</org_study_id>
    <nct_id>NCT01831518</nct_id>
  </id_info>
  <brief_title>Predicting Response to CRT Using Body Surface ECG Mapping</brief_title>
  <official_title>Evaluation of a Novel Method of Non-surface Electrocardiographic Mapping in Predicting Clinical, Structural and Neurohormonal Responses in Patients Undergoing Cardiac Resynchronization Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tom Jackson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CardioInsight Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy (CRT) involves pacing the left and right side of the heart
      in order to improve the coordination of the contraction in patients with heart failure.
      Current selection criteria incorporate the severity of the symptoms, the mechanical function
      of the heart and the time it takes the electrical stimulation to spread over the left
      ventricle (as assessed on the standard 12 lead electrocardiogram-ECG). Unfortunately these
      criteria only seem to select approximately 70% of the patients who might respond to this
      invasive therapy. Body surface ECG mapping is a new technique that assesses the electrical
      activation of the heart in more detail than the standard ECG. This study aims to determine
      whether this new technology may aid current selection criteria in predicting response to CRT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in distance travelled during six-minute walk test (6MWT)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiographic: signs of LV reverse remodelling</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Increase by &gt;5% in left ventricular ejection fraction with an associated decrease in LV end-diastolic (LVEDV) and end-systolic (LVESV) volumes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Change in symptoms severity assessed by Minnesota Living With Heart Failure Questionnaire (MLHFQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurohormonal status</measure>
    <time_frame>Baseline and 6 Months</time_frame>
    <description>Change in neurohormonal activation assessed by brain-natriuretic peptide (BNP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing</measure>
    <time_frame>6 months</time_frame>
    <description>Atrial and ventricular arrhythmic burden, percentage of bi-ventricular pacing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT Eligible</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACC/AHA/HRS/ESC guidelines for device-based therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT Implant</intervention_name>
    <arm_group_label>CRT Eligible</arm_group_label>
    <other_name>Cardiac Resynchronization</other_name>
    <other_name>Biventricular Pacemaker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Body Surface ECG Mapping</intervention_name>
    <arm_group_label>CRT Eligible</arm_group_label>
    <other_name>ECG Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years old

          -  Fulfils established clinical criteria for CRT implantation (with or without a
             defibrillator)

          -  NYHA Class III-IV Heart Failure (or NYHA II with NYHA III/IV symptoms in the preceding
             12 months)

          -  LVEF &lt;35% (Calculated using echocardiography or Cardiac MR) at the time of
             implantation

          -  QRS duration &gt; 130ms

          -  Optimal Tolerated Medical Therapy for Heart Failure

        Exclusion Criteria:

          -  Severe, life threatening non cardiac disease

          -  Active malignant disease and recent (&lt;5 years) malignant disease

          -  Prior Heart Transplant

          -  Recent history of unstable angina, acute coronary syndrome or myocardial infarction
             within three months of enrolment into the study

          -  Pregnancy

          -  Failure to participate in consent process

          -  Atrial Fibrillation

          -  Conventional pacemaker in situ

          -  Heart Failure requiring constant intravenous therapy including diuretics and/or
             inotropes

          -  Recent revascularisation procedure i.e. coronary artery bypass grafting (CABG) or
             percutaneous coronary intervention (PCI) within the last three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aldo Rinaldi, MBBS FRCP MD FHRS</last_name>
    <phone>aldo.rinaldi@gstt.nhs.uk</phone>
    <email>aldo.rinaldi@gstt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom A Jackson, MBBS BSc MRCP</last_name>
    <phone>02071888450</phone>
    <email>tomjackson@doctors.net.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom A Jackson, MRCP MBBS BSc</last_name>
      <phone>02071888450</phone>
      <email>tomjackson@doctors.net.uk</email>
    </contact>
    <investigator>
      <last_name>Aldo Rinaldi, FRCP FHRS MD MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom A Jackson, MRCP MBBS BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Brompton and Harefield NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rakesh Sharma</last_name>
      <email>Sharma Rakesh &lt;Rakesh.Sharma@rbht.nhs.uk&gt;</email>
    </contact>
    <contact_backup>
      <last_name>Dimitrios Konstantinou</last_name>
      <email>Konstantinou Dimitrios &lt;D.Konstantinou@rbht.nhs.uk&gt;</email>
    </contact_backup>
    <investigator>
      <last_name>Rakesh Sharma, MBBS MRCP PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guy's and St Thomas' NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Tom Jackson</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>ECG Imaging</keyword>
  <keyword>Body Surface Mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

